Measuring Persistency with Drug Therapy in Glaucoma Management

Advertisement

---

Measuring Patient Persistency with Drug Therapy Using Methods for the Design and Analysis of Natural History Studies

Eric S. Johnson, PhD;Essy Mozaffari, PharmD, MPH

August 1st 2002

ArticleSUPPLEMENT CONTENT

---

Participating Faculty

August 1st 2002

ArticleSUPPLEMENT CONTENT

---

Introduction

Gail F. Schwartz, MD

August 1st 2002

ArticleSUPPLEMENT CONTENT

---

An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension

William C. Stewart, MD;Jessica Leech, BS;Elizabeth D. Sharpe, MD;John Kulze, MD;John Ellyn, MD;Douglas G. Day, MD

August 1st 2002

ArticleSUPPLEMENT CONTENT

---

Population-Based Persistency Rates for Topical Glaucoma Medications Measured with Pharmacy Claims Data

Samaresh Dasgupta, MHS;Vikki Oates, MAS;Brahim K. Bookhart, MBA;Baze Vaziri, MBA, CPA;Gail F. Schwartz, MD;Essy Mozaffari, PharmD, MPH

August 1st 2002

ArticleSUPPLEMENT CONTENT

---

Rates of Discontinuation and Change of Glaucoma Therapy in a Managed Care Setting

Joshua J. Spooner, PharmD;Michael F. Bullano, PharmD;Laurence I. Ikeda, MD;Tara R. Cockerham, PharmD;William J. Waugh, PharmD;Thomas Johnson, Pha

August 1st 2002

ArticleSUPPLEMENT CONTENT

---

Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population

Fadia T. Shaya, PhD, MPH;C. Daniel Mullins, PhD;Winston Wong, PharmD;Jeannie Cho, PharmD

August 1st 2002

ArticleSUPPLEMENT CONTENT

---

Measuring Persistency and Intraocular Pressure-Controlled Days in Patients Receiving Topical Glaucoma Medications

Gail F. Schwartz, MD;Robert Platt, PhD

August 1st 2002

ArticleSUPPLEMENT CONTENT